Imputation methods for missing outcome data in meta-analysis of
                    clinical trials by Higgins, Julian PT et al.
Clinical Trials 2008; 5: 225–239 ARTICLE
Imputation methods for missing outcome
data in meta-analysis of clinical trials
Julian PT Higgins, Ian R White and Angela M Wood
Background Missing outcome data from randomized trials lead to greater
uncertainty and possible bias in estimating the effect of an experimental treatment.
An intention-to-treat analysis should take account of all randomized participants
even if they have missing observations.
Purpose To review and develop imputation methods for missing outcome data
in meta-analysis of clinical trials with binary outcomes.
Methods We review some common strategies, such as simple imputation of
positive or negative outcomes, and develop a general approach involving
‘informative missingness odds ratios’ (IMORs). We describe several choices for
weighting studies in the meta-analysis, and illustrate methods using a meta-analysis
of trials of haloperidol for schizophrenia.
Results IMORs describe the relationship between the unknown risk among missing
participants and the known risk among observed participants. They are allowed to
differ between treatment groups and across trials. Application of IMORs and other
methods to the haloperidol trials reveals the overall conclusion to be robust to
different assumptions about the missing data.
Limitations The methods are based on summary data from each trial (number of
observed positive outcomes, number of observed negative outcomes and number
of missing outcomes) for each intervention group. This limits the options for
analysis, and greater flexibility would be available with individual participant data.
Conclusions We propose that available reasons for missingness be used to
determine appropriate IMORs. We also recommend a strategy for undertaking
sensitivity analyses, in which the IMORs are varied over plausible ranges. Clinical
Trials 2008; 5: 225–239. http://ctj.sagepub.com
Background
Clinical and policy decisions regarding healthcare
interventions are increasingly based on evidence
from meta-analyses of randomized controlled trials
(RCTs). Threats to validity of RCTs carry through to
meta-analyses containing them. Well known
threats include poor concealment of allocation
and inappropriate blinding of participants and
personnel [1]. A further threat that has received
relatively little attention in the meta-analysis
context is missing outcome data. RCTs almost
inevitably fail to collect relevant outcome data on
every randomized participant, no matter how
rigorous their methodology. Missing outcome
data lead to increased uncertainty over the effect
of an intervention, and if ignored may lead to
biased estimates. A full intention-to-treat (ITT)
analysis is often interpreted as including all rando-
mized participants, and such analyses should
recognize and incorporate the implications of
missing observations [2].
Methodology for dealing with missing outcome
data is well developed for individual RCTs, although
perhaps seldom applied, with possible approaches
including multiple imputation, maximum likeli-
hood techniques and sensitivity analysis [3,4].
Much of this advanced methodology, however,
requires detailed data for each participant. For
example, multiple imputation and full likelihood
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predictors of dropout are observed and modeled,
which becomes more plausible as the data become
richer.
Here we address the meta-analysis of summary
data from each RCT, typically obtained from
published reports. We consider simple methods in
which a meta-analytic estimate is obtained as a
weighted average of effect estimates [5]. Dealing
with missing outcome data in a meta-analysis raises
particular problems, principally arising from the
limited information typically available in published
reports. Although a meta-analyst would ideally seek
any important but unreported data from the
original trialists, this approach is not always success-
ful and it is uncommon to have access to more than
group-level summary data at best.
Meta-analyses should be replicable and therefore
transparent in the methods used to derive their
results, and a systematic approach to deal with
missing data is desirable. In this article we focus on
meta-analyses of two-arm, parallel group trials with
a binary outcome. We overview methods for deal-
ing with missing binary outcome data in clinical
trials, develop and discuss them in the context of
meta-analysis, and apply them to a systematic
review of placebo-controlled trials of haloperidol
in the treatment of schizophrenia. Our ultimate
aim is to provide suggestions on the selection of a
strategy, or strategies, for (i) a primary meta-analysis
in the presence of missing data; and (ii) sensitivity
analyses to assess the potential impact of missing
data on the results.
Methods for dealing with missing
outcome data
It is useful to classify missing outcome data accord-
ing to the relationship between nonavailability of a
particular value and the observed and unobserved
values. We will use the term ‘missingness’ for the
nonavailability of a participant’s outcome. First, if
missingness of an outcome is not related to any
observed or unobserved variables, then the missing
data are described as ‘missing completely at
random’ (Figure 1(a) and (b)). Analysis restricted to
individuals with complete data is always valid when
the data are missing completely at random. If
missingness of an outcome may be related to
observed or unobserved variables, but is not related
to the actual value of the outcome, conditional on
the observed variables, then the missing data are
described as ‘missing at random’ (Figure 1(c) and
(d)). An alternative term is ‘ignorable’, because a
correct likelihood-based analysis of all the observed
data is valid [3]. (Strictly, a further condition is
required, but this is true in almost all practical
applications.) ‘Missing completely at random’ is a
special case of ‘missing at random’. Finally, if
missingness of an outcome is related to the value
of that outcome, even conditional on other
observed variables, then the missing data are
described as ‘informatively missing’. This could be
because of some common unobserved cause of both
missingness and the outcomes (Figure 1(e)) or
because the outcome directly causes missingness
(Figure 1(f)). Alternative terms are ‘missing not at
random’, ‘notmissingatrandom’ or‘nonignorable’,
the last so called because a likelihood-based analysis
of the observed data alone is typically biased [3].
With data that are informatively missing, the
missing at random assumption is false by defini-
tion, but there may be other more plausible
assumptions that make analysis possible. For exam-
ple, with repeated measures data, the observed data
may be assumed to vary around an underlying
person-specific trend, and analysis can be based on
the assumption that the risk of dropout depends on
the underlying trend [6]. If no such assumption can
reasonably be made then the data analyst has little
option but to consider a model containing an
unknown and unidentified parameter (for example,
the difference between the mean outcome in the
unobserved data and the mean outcome in the
observed data) and consider a range of possible
values for the unknown parameter in a sensitivity
analysis [7]. From a Bayesian perspective this
approach can be refined by assigning a prior
distribution to the unknown parameter, giving
inferences that appropriately reflect uncertainty
about the missing data [8,9].
In a simple RCT with a binary outcome, treat-
ment assignment is an observed variable that may
affect outcome. If treatment assignment also affects
missingness, as in Figure 1(d), then the data are
missing at random. It could be that some other
baseline characteristics are related both to the out-
come and to the risk of data being missing. In this
case the data could be missing at random (as in
Figure 1(d)), so that an analysis of available outcome
data, provided that it adjusted for the baseline char-
acteristics, would be valid. However, in a meta-
analysis situation, such baseline data are seldom
available (as in Figure 1(e)). The basic data set from
each trial in a meta-analysis situation comprises a
3 2 table providing numbers of participants with
observed positive outcome, with observed negative
outcome, or having a missing outcome, in each
group (Table 1). Leaving aside the observed variable
representing treatment allocation, the six situations
summarized in Figure 1 reduceto two.Either there is
no association between missingness and outcome
(Figure 1(a)–(c)) or there is association between
missingness and outcome (Figure 1(d)–(f)).
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treatment group are therefore to treat the missing
data as missing completely at random or to treat the
data as informatively missing.
It is not possible to determine which of these
approaches is more appropriate from the 3 2 table
from a single RCT. In a meta-analysis of several
RCTs with different proportions of missing data, a
plot of effect estimates against the proportion of
missing data, and an associated meta-regression
analysis, may reveal a relationship that indicates
informative missingness. This would rest on an
assumption that the effect sizes underlying the
complete (observed and unobserved) data are
similar across trials, so that systematic deviation
from this underlying effect size is due to omission
of data from participants in whom the effect size is
larger or smaller. However, meta-regression is an
unreliable technique, particularly because of con-
founding [10]. For example, the more pragmatic
trials in a data set may be larger, simpler and have
wider eligibility criteria resulting both in higher
rates of missing data and in smaller treatment
effects, so that a relationship between missing data
rate and effect estimate would be confounded with
these other characteristics associated with trial size.
Furthermore, meta-regression will typically have
low power to detect any such relationship as
Outcome
(a) Missing completely at random (1) (b) Missing completely at random (2)
Missingness Outcome Missingness
Outcome Missingness Outcome Missingness
Outcome Missingness Outcome Missingness
(c) Missing at random (1)
Observed or 
unobserved 
variables
Observed or 
unobserved 
variables 1
Observed or 
unobserved 
variables 2
Observed
variables
Unobserved
variables
(d) Missing at random (2)
(e) Informatively missing (1) (f) Informatively missing (2)
Figure 1 Some possible scenarios for missing data. Arrows indicate causal effects. Missing completely at random: (a) outcome and
missingness are unrelated and not dependent on any other variables; (b) missingness is ‘random’, but outcome may be dependent
on other variables. Missing at random: (c) different variables are responsible for outcomes and for missingness; (d) the same variables
are responsible for outcomes and for missingness, but can be incorporated into the analysis; Informatively missing: (e) the same
variables are responsible for outcomes and for missingness, but cannot be incorporated into the analysis; (f) missingness depends
directly on the unobserved outcome
Table 1 Basic data and statistics from a single trial
Data Statistics
Event No event Missing Total Observed risk Proportion missing
Experimental rE fE mE NE pE¼rE/(rEþfE)a E¼mE/NE
Control rC fC mC NC pC¼rC/(rCþfC)a C¼mC/NC
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error rate [11].
A more realistic approach is to tackle missing
data on a trial-by-trial basis, making sensible and
consistent decisions about whether data are infor-
matively missing, and if so what the missing
outcomes might have been, and assessing the
sensitivity of results to these decisions. In the
following discussion we describe a number of
possible ways to handle missing data. We assume
that the effect measure used to compare the groups
is either the odds ratio (OR), the risk ratio (RR) or
the risk difference (RD).
Available case analysis (ACA)
Before considering strategies for addressing missing
data we mention the option of an available case
analysis, which includes only those participants
whose outcome data are known. This is often
termed complete case analysis, and usually pro-
vides a sensible starting point. It is probably the
most common in meta-analyses in practice. As we
remark above, this analysis may be biased if the fact
that the data are missing is related to the unob-
served clinical outcome.
Imputed case analysis (ICA)
In an imputed case analysis, missing values are filled
in using specific assumptions about what might
have happened to the participants. ICA yields un-
biasedestimatesiftheseassumptionsarereasonable,
at least on average. However, care must be taken not
to underestimate standard errors [4] by ignoring
uncertainty about the imputed values. Possible
methods are multiple imputation [12] and using
specially calculated standard error formulae [13].
Here we outline several specific approaches to
imputing missing outcomes in the two treatment
groups, and describe an approach that makes use of
available reasons for missingness. We then provide
a framework that unifies all the imputation meth-
ods. The methods are summarized in Table 2.
We first distinguish between two conceptual
approaches to undertaking the imputations. The
first is to impute an outcome for each missing
participant, then to perform a standard analysis on
the filled-out data set. The second approach is to
impute risks of events for the groups of people with
missingoutcomes,andtocalculatetreatmenteffects
from the observed and imputed risks. With small
numbersofmissingparticipants, theformerstrategy
can be subject to large rounding error when
assumptions about missing outcomes do not map
directly onto individual participants, with unneces-
sary error in effect estimates. In fact, the standard
methods for estimating treatment effects (e.g., OR,
RRetc)allownonwholenumbersofparticipants.For
example, five missing participants might be divided
into two and a half with the event, and two and half
without the event. Following this strategy, the two
conceptual approaches yield identical estimates of
treatment effect. However, we will see in a later
section that the two approaches lead to different
standard errors, and hence different weights in the
meta-analysis.
Two commonly used strategies are to assume
that all missing participants experience the event,
or that none of the missing participants experience
the event [14]. These correspond to imputing risks
of 1 and 0 for the missing participants, and we
denote such imputed case analyses as ICA-1 and
ICA-0, respectively (Table 2). Such assumptions
may be appropriate when outcomes of missing
participants can be predicted. For example, in trials
of smoking cessation interventions it is common to
Table 2 Summary of imputation strategies, with connection with IMORs. pM
E and pM
C are imputed risks among
missing participants based on available reasons for missingness; see text for precise definition
Method Imputation IMORE IMORC
ICA-0 Impute missing¼no event (0) 0 0
ICA-1 Impute missing¼event (1) 11
ICA-pC Impute all according to observed control group risk, pC
pCð1   pEÞ
ð1   pCÞpE
1
ICA-pE Impute all according to observed experimental group risk, pE 1
pEð1   pCÞ
ð1   pEÞpC
ICA-p Impute according to observed group-specific risk 1 1
ICA-b Impute to create best case scenario for experimental treatment 0 [or 1] 1 [or 0]
ICA-w Impute to create worst case scenario for experimental treatment 1 [or 0] 0 [or 1]
ICA-r Impute incorporating available reasons for missing data
pM
E ð1   pEÞ
ð1   pM
E ÞpE
pM
C ð1   pCÞ
ð1   pM
C ÞpC
ICA – Imputed case analysis.
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although even here we would rarely believe the
implicit assumption that all those who stop smok-
ing provide outcome data.
An alternative imputation strategy is to assume
that all missing participants have the same risk as
the observed participants in the control group, a
strategy we denote by ICA-pC [13]. This may appear
reasonable if none of the excluded participants
had received the experimental treatment, or if
those excluded from the experimental group
stopped taking a treatment with reversible effects.
However, similarity in received treatment is not
a sufficient justification: missing and observed
participants must also have no systematic
differences in other characteristics that might be
associated with the missing outcome values. This is
a substantial assumption analogous to the missing
at random assumption.
More rarely, one might assume that missing
participants have the same risk as the observed
participants in the experimental group, a strategy
we denote by ICA-pE. This may be thought appro-
priate, for example, when participants from the
control group are excluded because they started
receiving the experimental treatment.
Imputing the same risks in both groups, using
either the risk observed in the control group (ICA-
pC) or those observed in the experimental group
(ICA-pE), dilutes effect estimates, pulling them
towards the null hypothesis. This can be seen by
writing down the revised risks in the two groups,
say p 
C and p 
E. For example, imputing the control
group risk throughout produces
p 
C ¼ pC
and
p 
E ¼ pE 1   aE ðÞ þ pCaE, ð1Þ
where aE is the proportion of participants in the
experimental group with missing data (see Table 1).
Effect estimates are obtained by comparing the
revised risks p 
C and p 
E. As an example, a revised
estimate of the RR is
RR
  ¼
p 
E
p 
C
¼ 1   aE ðÞ RR þ aE ð2Þ
which is closer to 1 than RR, the RR among
observed participants.
Rather than imputing according to a common
risk across both groups, we could impute according
to group-specific risks, a strategy we call ICA-p. Here
missing participants from the control group are
assumed to have the same risk as observed partici-
pants in the control group, and those missing from
the experimental group to have the same risk as
those observed in the experimental group. This is
exactly the missing at random assumption and the
effect estimate is the same as for available case
analysis. However, the first conceptual approach, in
which outcomes are imputed for individual missing
participants, has the effect of scaling up the size of
the data set and thus wrongly reducing standard
errors, as discussed below.
Imputation according to available reasons
for missingness
If reasons for participants being missing are avail-
able from each study, these may be exploited in an
imputation scheme that combines aspects of the
above five schemes. We propose a strategy, ICA-r,
in which values missing due to different reasons
may be imputed using different imputation strate-
gies chosen from ICA-0, ICA-1, ICA-pC, ICA-pE or
ICA-p. For example, if it is known that patients
have missing outcome assessments because they
deteriorated to an extent necessitating their
removal from the trial, they would be assigned to
ICA-0 or ICA-1 (depending on the outcome defini-
tion) to reflect an unsuccessful outcome. On the
other hand, patients who are missing for reasons
unlikely to be related to treatment (for example,
moving away from the area) might be assigned
imputation scheme ICA-p. For participants whose
data are missing due to death, we would make use
of any available information on cause of death.
Should this be absent, it may in some situations be
reasonable to assume treatment failure, so that
strategy ICA-0 or ICA-1 is employed. The method
requires the subjective assignment of participants’
reasons for being missing to particular assumptions
about their outcomes. We illustrate this strategy for
the specific example of schizophrenia trials later.
It is straightforward to work out the imputed risk
in each group when using reasons for missingness. If
the proportions of missing participants, aE and aC,
are partitioned according to the reasons so that, for
example, aE ¼ a
ð0Þ
E þ a
ð1Þ
E þ a
ðpCÞ
E þ a
ðpTÞ
E þ a
ðpÞ
E then the
estimated risks among the missing participants are
pM
E ¼
 
0   a
ð0Þ
E þ 1   a
ð1Þ
E þ pC   a
ðpCÞ
E þ pE   a
ðpEÞ
E
þ pE   a
ðpÞ
E
 .
aE
¼
a
ð1Þ
E þ pCa
ðpCÞ
E þ pE a
ðpEÞ
E þ a
ðpÞ
E
  
aE
ð3Þ
in the experimental group and
pM
C ¼
a
ð1Þ
C þ pCða
ðpCÞ
C þ a
ðpÞ
C ÞþpEa
ðpEÞ
C
aC
ð4Þ
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groups are then
p 
E ¼ pE 1   aE ðÞ þ pM
E aE
p 
C ¼ pC 1   aC ðÞ þ pM
C aC:
ð5Þ
For studies that do not report reasons for missing-
ness or cause of death, possible options include:
  determine the relative proportions of specific
reasons for missingness across trials that do
report them, and impute according to these
proportions (this corresponds to calculating a
ð0Þ
E ,
a
ð1Þ
E , etc, across all studies providing reasons for
missingness, and applying Equations (3) and (4)
once to impute risks pM
E and pM
C for use in the
remaining studies);
  impute according to the relative proportions of
specific reasons in the ‘most similar’ trial;
  impute according to the most common reason
for missingness among all trials;
  use only an available case analysis.
In the example that follows, we follow the first of
these strategies.
Best-case and worst-case scenarios
A common sensitivity analysis in the face of
missing data is to impute outcomes to recreate
the most extreme possible data sets, one reflecting
the best-case scenario for the experimental treat-
ment (ICA-b) and the other the worst-case scenario
(ICA-w). The best-case scenario, for example, would
assume missing participants in the experimental
group had good outcomes and those in the control
group had bad outcomes. Such imputation would
provide the largest and smallest effect estimates
compatible with the observed data.
As an aside, we remark that a rather different
approach to dealing with missing data is to inflate
standard errors of treatment effect estimates from
available-case analyses. Gamble and Hollis have
proposed an approach to meta-analysis based on
the best-case and worst-case scenarios [17]. The
most extreme lower and upper confidence interval
limits from simple implementations of these two
analyses are used to form an uncertainty interval
for each study. These uncertainty intervals, treated
as if they were confidence intervals, are converted
into inflated standard errors, leading to reduced
weights for use in the meta-analysis. The meta-
analysis applies these weights to treatment effect
estimates from an available case analysis. The
reduced weights reflect the added uncertainty one
might associate with data being missing.
A generalization: the informative missingness
odds ratio
We now provide a general framework for making
assumptions about informatively missing data. This
framework contains all the ICA methods so far
considered as special cases (Table 2). The key idea is
to specify the risk among the missing participants in
the form of the odds ratio of the event among
missing participants relative to the event among
observed participants. This is allowed to be different
in the two groups. We refer to these as informative
missingness odds ratio (IMOR), and denote them
IMORE and IMORC for the two treatment groups.
This approach provides a generalization of the
above imputation strategies; connections with the
specific methods provided in Table 2. Our formula-
tion differs from a similar one by Magder [18]. His
‘response probability ratio’ is the ratio of the
probabilities of nonmissingness between those
with events and those without events, whereas
our IMOR is an odds ratio. The odds ratio has the
advantage that it cannot predict probabilities less
than zero or more than one [9]. Generalizations of
our approach have been studied extensively in the
statistical literature. Rotnitzky et al. considered
regression modeling of longitudinal data using a
sensitivity analysis over parameters that govern the
degree of informative missingness [19]. Reduced to
the setting of a single binary outcome and a single
binary covariate (e.g., randomized group), their
sensitivity parameters correspond to our IMORs.
The inherent nonidentifiability of missing data
problems has been stressed by Little [20]. A natural
extension is to quantify prior uncertainty about
IMORs [8,21–24].
Weighting schemes for imputed case analyses
We now outline how standard errors can be
obtained. We consider first the approach in which
outcomes are filled in for the missing participants.
We observe this to be in common use in the field of
meta-analysis, so some discussion is relevant. The
simplest approach is to treat imputed data as if they
were known, and calculate standard errors for the
studies in a meta-analysis in the usual way.
We shall refer to this approach as scheme W1:
W1. Naı ¨ve approach: Treat the imputed case
data set as if it was completely observed so
that uncertainty associated with imputing
missing values is ignored.
This scheme is inappropriate since it fails to
recognize that some data are observations and
others are imputed. This is particularly clear if we
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change the effect estimate and serve only to
inflate the sample size and reduce standard errors.
Indeed, in most cases the imputation strategies
we have outlined reduce standard errors using
this scheme; an exception is ICA-0 in conjunction
with risk ratios. We consider two simple
alternative schemes as follows.
W2. A hybrid approach: Here we aim to use
standard errors corresponding to the amount
of observed data. We determine effect
estimates from the imputed case data set, but
use standard errors directly from the available
case analysis.
A disadvantage of W2 is that the imputations
may alter risks, and these risks should be reflected
in the standard errors. We therefore consider:
W3.Adata-setre-sizingapproach:Wedetermine
risks (for experimental and control) from the
imputed case data set, but apply these to the
numbers of participants whose outcome is
known (i.e., from the ACA data set) to create
a revised 2 2 table. This re-sized data set then
forms the basis for the application of standard
methods. The row totals in the revised
2 2 table will be identical to those in the
available case analysis.
Turning now to the alternative conceptual
approach to the imputation, we consider theore-
tical approximate standard errors, derived condi-
tional on the IMORs. The risks rather than the
outcomes are now imputed, and these may be
derived from one of the ICA approaches listed in
Table 2, or from IMORs external to the study.
W4. IMOR-based approach: Standard errors
are based on application of IMORs to
observed risks, taking into account uncer-
tainty in observed risks and missingness
probabilities.
We derive standard errors for this approach in
the Appendix. For imputation with fixed
IMORs (such as ICA-0, ICA-1, ICA-p, ICA-b and
ICA-w), this approach yields statistically correct
standard errors. For imputations ICA-pC, ICA-pE,
and ICA-r, the standard errors are conditional on
the IMORs and ignore the fact that the IMORs are
computed from the data. Instead, standard errors
can be calculated for ICA-pC, ICA-pE directly
from Equations (1) and (2), and related methods
could be used for ICA-r. However, the resultant
standard errors are often smaller than if
complete data were observed. This is a logical
but unsatisfactory consequence of the assumption
that the unobserved outcomes have exactly the
same expectation in both groups. Much more
plausible results are obtained by conditioning on
the IMORs.
Weights awarded to studies in a meta-analysis
may be derived from the standard errors. In a
common-effect meta-analysis, where a common
(fixed) effect is assumed, the weights are typically
calculated as inverse squares of the standard errors.
Random-effects meta-analyses are more difficult to
predict since changes in effect estimates may result
in changes in the extent of heterogeneity among
studies, which is incorporated into the study
weights.
Application to haloperidol trials
We apply the above methods to a meta-analysis
of RCTs comparing haloperidol with placebo in
the treatment of schizophrenia. The antipsychotic
properties of haloperidol were discovered in the
1950s and the drug was believed to be effective and
welltolerated compared withalternatives. However,
trials involving schizophrenic patients are prone to
high proportions of missing data due, among other
reasons, to poor compliance of patients, rigid
implementation of RCT protocols and side effects.
A Cochrane review of haloperidol forms the basis of
our data [25].
Meta-analysis methods
We used only trials identified by the Cochrane
review, which sought controlled trials in patients
with schizophrenia or similar serious psychotic
illnesses randomized to any dose of haloperidol or
placebo. A comprehensive search strategy included
multiple electronic databases, cited reference
searching, hand searching of journals and direct
contact with investigators. Twenty trials were
included in the review (at the end of 2002). The
original review excluded trials with greater than
50% missing data, and we maintained this exclu-
sion because suitable clinical outcomes were not
reported. We retrieved the main publication of
each of the 20 included trials and two of us (JH and
AW) independently extracted information on: ran-
domized sample size; a dichotomous clinical out-
come of global improvement (choosing the primary
outcome of the study when specified); numbers of
missing data; and reasons for missing data.
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arbitration by IW when appropriate. Some
arbitrary decisions were necessary. We defined
clinical improvement as ‘moderate’ (or ‘good’) to
‘marked’ (or ‘excellent’) [26,27]; we ignored
the cross-over design of one trial [26] and assumed
in one study that ambiguous percentages
reflected ratios of patient numbers [28]. Since our
aim is to evaluate effects of missing data on clinical
outcomes, we discarded trials from which we could
not obtain dichotomous data on clinical
improvement.
We focus on risk ratios for clinical improvement,
as used in the original Cochrane review, so that risk
ratios greater than 1 reflect a beneficial effect of
haloperidol. Our meta-analyses are simple weighted
averages of log RR estimates. We mainly present
results for analyses assuming a common effect
(so-called ‘fixed-effect’ meta-analyses) since the
implications of the missing data are easier to
interpret. When we refer to random-effects meta-
analyses, these incorporate method of moment
estimates of among-study variance [29]. We note
without further comment that potentially impor-
tant heterogeneity of effects is present in the data
set, along with an apparent relationship between
effect size and study size. Prior to all analyses we
applied a continuity correction to trials in which rE,
fE,r C or fC (Table 1) were zero, adding a half to each
of these values.
Our analysis using reasons for missingness
(ICA-r) assigned reported reasons to imputation
strategies as described in Table 3. In some trials
the reasons for missingness were available for
precisely the missing participants, and the imputa-
tion was then straightforward. In other trials, the
reasons for missingness were given for a different
subset of participants, for example when clinical
outcome and dropout were reported for different
time points. In such cases we applied the propor-
tion in each classification to the missing popula-
tion in that trial. In trials that did not report any
reasons for missingness, the overall proportion of
reasons from all other trials was used.
Results
We were left with 17 trials providing data on
clinical improvement, and basic results from these
are listed in Table 4 [26–28,30–43]. Note that only
two trials have substantial amounts of missing data.
The study by Beasley reported outcomes for only 81
(59%) out of 137 participants [31]. The study by
Selman et al. reported outcomes for only 29 (50%)
out of 58 participants [40]. These two studies were
among four that specifically stated they involved
acutely ill participants, but were otherwise not
markedly different in characteristics from the other
studies.
An ACA assuming a common RR across studies
yields a meta-analytic estimate of 1.57 (95%
confidence interval from 1.28 to 1.92), indicating
strong evidence of a clinical improvement due to
haloperidol (Figure 2). Table 5 shows results of
meta-analyses using the various imputation strate-
gies and weighting schemes described above. The
overall conclusion is robust to most strategies, the
extreme worst-case scenario being the only analysis
with a 95% confidence interval including a RR of 1.
However, the point estimates are variable. For
example, imputing only failures for missing out-
comes (ICA-0) increases the RR estimate to approxi-
mately 1.90, and imputing only successes (ICA-1)
decreases it to between 1.16 and 1.41, depending
on the choice of weighting scheme.
Some implications of the various
weighting schemes for the two studies with the
most missing data [31,40] are also provided in
Table 5. These two studies drive the differences
among the various strategies and weighting
schemes. In the ACA they contribute just over
50% of the weight between them. Using naı ¨ve
weights (W1) with the various imputation strate-
gies illustrates that the implications of this
weighting scheme depend on the imputation
method. Weights for these two studies increase
when successes are imputed and decrease
when failures are imputed (and weights for the
studies with few or no missing data change in the
Table 3 Assignments of reasons for missingness to different imputation strategies for analysis of the haloperidol data
Classification of reasons Imputation
strategy
Lack of therapeutic benefit, lack of efficacy, relapse, insufficient/inadequate response,
behavioral deterioration.
ICA-0
Positive response. ICA-1
Adverse experience, refusal, withdrawal of consent, protocol violation, patient ran away,
patient uncooperative, patient decision, skin rash, tuberculosis, side effects, noncompliance.
ICA-pC
Loss to follow-up, administrative reasons, failure to report to hospital, patient sleeping, other. ICA-p
ICA – Imputed case analysis.
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both successes and failures are imputed depend on
the existing and imputed risks and are less easy to
predict. Weighting scheme W2 simply uses the
same weights as the ACA. Weighting scheme W3
generally, though not always, gives the two studies
less weight than W1, but in common with W1 it
reflects the risks obtained after imputing missing
outcomes. The final weighting scheme, W4, theo-
retically derived, is similar to W1 when IMORs are
extreme, so that risks of 0 or 1 are imputed (ICA-0,
ICA-1, ICA-b, ICA-w). For other analyses, W4
appropriately down-weights studies with missing
data compared with the naı ¨ve scheme W1.
We repeated the analyses using a random-effects
meta-analysis model (not shown). We observed
similar patterns, but make two remarks. First, all
point estimates were larger due to a tendency
for larger risk ratios to be found in smaller trials
(which are awarded relatively more weight in a
Risk ratio
0.1 1 10 50
Study
Weight %
Risk ratio 
(95% CI)
1.42 (0.89,2.25) Arvanitis 18.9
1.05 (0.73,1.50) Beasley 31.2
6.21 (1.52,25.35) Bechelli 2.0
7.00 (0.40,122.44) Borison 0.5
3.49 (1.11,10.95) Chouinard 3.1
8.68 (1.26,59.95) Durost 1.1
1.75 (0.58,5.24) Garry 3.4
2.04 (0.67,6.21) Howard 3.3
1.36 (0.75,2.47) Marder 11.4
3.00 (0.14,65.90) Nishikawa 82 0.4
9.20 (0.58,145.76) Nishikawa 84 0.5
3.79 (1.06,13.60) Reschke 2.5
1.48 (0.94,2.35) Selman 19.1
8.40 (0.50,142.27) Serafetinides 0.5
2.35 (0.13,43.53) Simpson 0.5
11.00(1.67,72.40) Spencer 1.1
19.00(1.16,311.96) Vichaiya 0.5
1.57 (1.28,1.92) Overall (95% CI)
Figure 2 Meta-analysis (assuming a common effect) of available case analyses (ACA) from each of the haloperidol trials
Table 4 Data from 17 trials of haloperidol for schizophrenia
Trial Haloperidol Placebo
Improved Not improved Missing Total Improved Not improved Missing Total
rE fE mE NE rC fC mC NC
Arvanitis [30] 25 25 2 52 18 33 0 51
Beasley [31] 29 18 22 69 20 14 34 68
Bechelli [27] 12 17 1 30 2 28 1 31
Borison [32] 3 9 0 12 0 12 0 12
Chouinard [33] 10 11 0 21 3 19 0 22
Durost [28] 11 8 0 19 1 14 0 15
Garry [34] 7 18 1 26 4 21 1 26
Howard [35] 8 9 0 17 3 10 0 13
Marder [36] 19 45 2 66 14 50 2 66
Nishikawa 82 [37] 1 9 0 10 0 10 0 10
Nishikawa 84 [38] 11 23 3 37 0 13 0 13
Reschke [39] 20 9 0 29 2 9 0 11
Selman [40] 17 1 11 29 7 4 18 29
Serafetinides [41] 4 10 0 14 0 13 1 14
Simpson [42] 2 14 0 16 0 7 1 8
Spencer [43] 11 1 0 12 1 11 0 12
Vichaiya [26] 9 20 1 30 0 29 1 30
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less variation in findings across the various imputa-
tion strategies and weighting schemes. This might
be expected given that the studies with substantial
amounts of missing data had large weights in the
common-effect meta-analysis and hence receive
smaller weights in a random-effects meta-analysis.
The effect of different imputation strategies will also
differ between common-effect and random-effects
meta-analyses when the strategies introduce or
remove substantial heterogeneity. Heterogeneity is
affected by the sizes of both point estimates and
their standard errors. In the haloperidol example
there was little variation in heterogeneity (data not
shown),otherthanonimplementationoftheworst-
case scenario, ICA-w (when standard  
2 statistics
were approximately tripled).
Table 5 also provides some results for specific
values of (IMORE, IMORC), assuming values of (2,2)
and (½,½). These assume the odds of clinical
improvement among missing patients is either
double or half the odds of clinical improvement
for observed patients. The results tend in the
expected directions. For example, with IMORs
below 1 in both groups the results are intermediate
between ACA and ICA-0. Note that assuming
IMORs of (1,1) is equivalent to the ICA-p analysis,
and the ICA-p analysis is itself equivalent to the
ACA analysis under weighting scheme W2.
The sensitivity analysis of Gamble and Hollis
(Table 5) gives a pooled RR of 2.02, which is
somewhat larger than most of the imputed case
analyses. This is because the method gives con-
siderably smaller weights to the Beasley (6.6%) and
Selman (4.4%) studies which both have RR esti-
mates on the low side.
Many of the assessments of global improvement
in these trials were derived by dichotomizing scales.
Four of the studies [28,30,33] reported having
imputed scores on these scales by carrying forward
the last available observation. We were unable to
account for this in our analysis of the published
results, so the true amount of missing data is greater
than we have assumed. Furthermore, since repeated
measurements were made in many of the trials,
valuable information about participants missing
from the primary timepoint of interest would in
theory be available from earlier time points. Again,
the summary binary data available to us did not
permit exploitation of this.
Recommendations
We have described and implemented a number of
strategies for addressing missing binary outcome
data from clinical trials in a meta-analysis. Here we
discuss the relative merits of the methods and make
suggestions for practice, both for primary meta-
analysis and for sensitivity analyses. We formulated
some principles to guide our selection:
Precision. The standard error for an effect
estimate from a particular study after accounting
for missing data should not be smaller than in the
ACA, and ideally should be larger. We suggest this
principle to ensure that appropriate uncertainty
induced by missing data is carried forward into the
meta-analysis. This rules out weighting scheme W1,
which we believe to be commonly implemented, as
it treats imputed data as known and increases
precision of effect estimates. (Note that assuming
missing values to be successes, as in ICA-1, should
logically reduce standard errors, but because one
can never be sure of such an assumption, we
propose not accepting the standard error
reduction.)
Reducing bias by making use of relevant infor-
mation. In some cases the bias (or at least its
direction) in ACA can be anticipated. External
information relevant to the likely bias should be
used when available. Such information might
include reasons for missingness, evidence from
related studies or subject expertise.
Scale independence. A good strategy should be
applicable whether the meta-analysis is conducted
on the RD, RR or OR scale.
Simplicity. A strategy should be simple to under-
stand and straightforward to implement, for exam-
ple by being possible in widely used software.
Proposal for a principal meta-analysis
We believe that an ACA should generally be
presented as a point of reference. Sometimes this
will be considered suitable for a primary analysis.
However, we suggest as a preferable primary
analysis one that emphasizes the second of our
principles. Thus we suggest the strategy of imput-
ing missing data according to reasons for missing-
ness (ICA-r). The categorization of reasons should
ideally be specified in advance of seeing the data.
Although, this involves subjective judgments about
the true outcomes of missing participants, we feel
that this approach may most closely represent what
would have been observed. Furthermore, if there is
a diverse mixture of reasons for missingness, as was
the case in our example, then the approach
essentially averages over several of the specific
imputation strategies. We propose using
weighting scheme W4, in which the uncertainties
in the observed risks and the extent and assump-
tions of missingness are incorporated into
the analysis. Our primary analyses are presented
in Table 6.
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betoexpress explicitlythe uncertainty aboutIMORs
by making use of prior distributions in a Bayesian
analysis [24]. Prior distributions may be available
from external evidence sources, from heuristic
arguments, or may constitute prior distributions
formally elicited from subject experts. The determi-
nation of the prior distribution would ideally
involve consideration of the methodology, propor-
tions of missing data and any available reasons for
missingness from each component study. The
IMORs may be the same or different for different
studies. Note that this approach can incorporate
judgments that, for example, all missing outcomes
should be assigned a value of 1 (IMOR¼1)o ra
value of 0 (IMOR¼0), as in the example of smoking
cessation studies we cited earlier.
Proposals for simple sensitivity analysis
Analyses that attempt to account for unobserved
data should be assessed in sensitivity analyses.
A thorough sensitivity analysis should separate
two dimensions: (1) the effect of allowing for
missing data on the effect estimates from the
individual studies; and (2) the effect of allowing
for missing data on the standard errors (and hence
weights) of these estimates. This is because the
result of a meta-analysis is affected jointly by the
magnitude of effect estimates from individual
studies and by their standard errors. Here we discuss
a simple strategy that might be adopted in practice.
The four extreme imputation approaches of
assuming that all missing participants had an
event (ICA-1) or no event (ICA-0) and the best-case
(ICA-b) and worst-case (ICA-w) scenarios provide
limits on effect estimates compatible with the
data. We consider these to be rather unlikely
scenarios, especially when there are many missing
participants. Instead, we suggest selecting IMORs
for the two groups that cover realistic situations.
Our strategy is illustrated in Figure 3, following
the graphical sensitivity analysis proposed by
Hollis [44]. This is a L’Abbe ´ plot (experimental
group risk vs. control group risk) for risks to be
applied to the missing participants. The corners
of the plot represent the extreme imputation
strategies, and all points on the plot correspond to
pairs of IMORE and IMORC. For a given ‘starting
point’, corresponding to the primary analysis
(the open circle, typically the ACA), we move in
four directions towards the corners of the plot.
Moving towards the ICA-0 and ICA-1 corners
involves assuming the same IMORs in the two
treatment groups; moving towards the best-case
and worst-case corners involves assuming different
IMORs in the two treatment groups. We achieved
these directions by taking IMORC¼IMORE or
IMORC¼1/IMORE, respectively. We propose using
weighting scheme W2 (ACA weights) so that
only the point estimates are affected by the
different IMORs. A selection of combinations of
IMORE and IMORC should be used, based on the
views of experts in the field. In Table 6 we illustrate
IMOR combinations involving 2 and ½ for the
haloperidol data, corresponding to the four
innermost filled circles in Figure 3. This demon-
stratesthattheresultsoftheACAarerobustto2-fold
differences in risks between outcomes among
the missing participants and outcomes of observed
participants.
To evaluate the effects of missing participants on
the weights awarded to the studies, the inflated confi-
dence intervals of Gamble and Hollis might be used.
Table 6 Proposed analysis strategy with missing data: Results of meta-analyses assuming common RR applied to 17 haloperidol trials.
Meta-analyses produce estimates of RR for clinical improvement with 95% confidence interval. Inconsistency of risk ratios across studies
is measured using I
2 [45]. Results for Beasley and Selman trials are estimates of RR and percentage weights awarded to them in the
meta-analysis
Beasley Selman Meta-analysis
RR Weight (%) RR Weight (%) Pooled RR (95% CI) I
2 (95% CI)
Reference analysis ACA 1.05 31.2 1.48 19.1 1.57 (1.28,1.92) 41 (0,66)
Proposed analysis
(weight W4)
ICA-r 1.35 27.1 1.77 16.4 1.79 (1.44,2.21) 27 (0,59)
Sensitivity analysis IMORE¼2, IMORC¼2 1.00 31.2 1.32 19.1 1.51 (1.24,1.85) 44 (0,67)
(weight W2) IMORE¼½, IMORC¼½ 1.12 31.2 1.74 19.1 1.65 (1.35,2.01) 38 (0,64)
IMORE¼½, IMORC¼2 0.85 31.2 1.28 19.1 1.41 (1.15,1.73) 52 (1,71)
IMORE¼2, IMORC¼½ 1.32 31.2 1.80 19.1 1.76 (1.44,2.16) 29 (0,60)
ACA – available case analysis; ICA – Imputed case analysis; IMOR – informative missingness odds ratio for experimental group (E) or
control group (C).
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and considerable down-weighting of studies with
missing data. We also propose a more statistical
treatment of the problem, providing a comprehensive
sensitivity analysis strategy using correlated prior
distributions for the two IMORs [24].
Discussion
We have overviewed methods for dealing with miss-
ing dichotomous outcome data in meta-analysis
of clinical trials, and illustrated a strategy for
primary analysis and a series of sensitivity
analyses. We make extensive use of the notion of
an informative missingness odds ratio, describing
the relative risks among missing and observed
participants. A wide variety of imputation schemes
are seen to be special cases of this general approach.
The methods we present can be programmed into
basic statistical software or a simple spreadsheet.
In applying different strategies to an example of
clinical trials of haloperidol for schizophrenia we
have established that the results of this particular
meta-analysis are robust to reasonable assumptions
concerning the outcomes of missing participants.
The data set is typical of many meta-analytic data
sets, since it contains studies of various sizes and
variety in the degree of missingness across studies.
However, there exist many meta-analyses with
more severe rates of missingness, and with a
larger proportion of studies having high rates of
missing data. It is likely that in some cases the
substantive results would be changed by sensitivity
analysis. Using all available reasons for missingness,
a strategy rarely used in meta-analysis, may help to
make optimal use of such data sets.
The ideas could be extended to analysis of other
types of data. For example, for continuous out-
comes, ‘informative missingness differences in
means’ or ‘informative missingness ratios of
means’ might replace the IMORs. These could be
used to impute missing outcomes that are similar,
bigger or smaller than the observed outcomes
within any particular treatment group. The best-
case and worst-case scenarios may however not be
possible unless there are known limits to the
outcome (as in psychometric scales, for example).
In conclusion, we propose a systematic approach
to dealing with missing outcome data in meta-
analysis. Adoption of these strategies should allow a
transparently obtained ‘best-guess’ primary analy-
sis, and a series of sensitivity analyses to evaluate
the robustness of the conclusion to how the
missing data were handled.
The procedures described are easily implemented
using the Stata programme metamiss.ado which is
available from http://www.mrc-bsu.cam.ac.uk/
BSUsite/software/.
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Figure 3 L’Abbe ´ plot providing graphical representation of
the proposed sensitivity analysis strategy, representing risks to
be applied to missing participants. The dotted line represents
absence of a treatment effect. The open circle corresponds to a
experimental group risk of 0.46, and a control group risk of
0.21, reflecting the overall risks among the haloperidol trials.
Filled circles represent combinations of IMORs of 2,1/2 (nearest
to the open circle); 3,1/3; 4,1/4; and 5;1/5 (nearest to the
corner). In this example, points above the dotted line represent
superiority of haloperidol, and points below represent super-
iority of placebo. Note that choosing larger IMORs (with their
reciprocals) leads to traveling along curved paths towards the
corners. The corners reflect four of the imputation strategies
described earlier, where IMORs are combinations of 0 and 1
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treatment effect estimates based
on observed risks and imors
We denote overall risks in the experimental and
control groups by p 
E and p 
C, respectively. These risks
result from combinations of observed event rates
and imputation assumptions for missing partici-
pants. The treatment effects, RD , RR ,a n dOR ,a r e
estimated directly from p 
E and p 
C.T oe s t i m a t et h e i r
variances we use standard Taylor series approxima-
tions, taking the covariance between p 
E and p 
C to be
zero, corresponding to independent IMORs for the
experimental and control groups.
varðRD Þ¼varðp 
EÞþvarðp 
CÞ
varðlogRR Þ 
varðp 
EÞ
p 
E
2 þ
varðp 
CÞ
p 
C
2
varðlogOR Þ 
varðp 
EÞ
½p 
Eð1   p 
EÞ 
2 þ
varðp 
CÞ
½p 
Cð1   p 
CÞ 
2
The task is to obtain estimates of varðp 
EÞ and
varðp 
CÞ.
IMORE is defined as the odds of outcome in the
missing individuals divided by the odds of outcome
in the observed individuals in the experimental
group. For a given IMORE, we can estimate the risk
in the missing individuals in the experimental
group as
pEIMORE
pEIMORE þ 1   pE
so our estimate of the true risk, analogous to (1)
or (5), is
p 
E ¼ pEð1   aEÞþ
pEIMORE
pEIMORE þ 1   pE
aE ð6Þ
We can obtain the variance of the true risk as
var p 
E
  
¼
pEð1   pEÞ
nE   mE
  1   aE þ
aEIMORE
ðpEIMORE þ 1   pEÞ
2
 ! 2
þ
aEð1   aEÞ
nE
pEð1   pEÞðIMORE   1Þ
pEIMORE þ 1   pE
   2
which is based on a further Taylor approximation
to (6): the terms in large parentheses are the partial
derivatives of p 
E with respect to pE and aE,
respectively, and the terms outside them are
variances of pE and aE, respectively. A similar
calculation gives varðp 
CÞ.
A generalization allows for different IMORs in
different individuals, to cover different reasons for
missingness. Let Er be the proportion of all
individuals in the experimental group who are
missing for reason r (so that
P
r aEr ¼ aE). Let
IMOREr be the IMOR specific to these individuals,
then their risk is
p 
Er ¼
pEIMOREr
pEIMOREr þ 1   pE
and the estimated true risk among all individuals in
the experimental group is
p 
E ¼ pE 1   aE ðÞ þ
X
r
aErp 
Er ¼ pE þ
X
r
aEr p 
Er   pE
  
The variances are given by
var p 
E
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pEð1 pEÞ
nE mE
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X
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ðpEIMORErþ1 pEÞ
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"#  ! 2
þ
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ðpE p 
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X
r
aEr p 
Er p 
E
   2 ðpE p 
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2
hi ()
and similarly for the control group. These formula
simplify to the previous formulae when there is a
single reason.
To deal with trials in which the number of
successes or the number of failures is zero in one
group, a continuity correction (adding 0.5) may be
applied to numbers of successes and failures either
before or after calculating the imputed risks. In our
analyses we have made the correction before
imputing missing outcomes, but only to
2 2 tables that would have had a zero cell
after imputing any successes or failures using
ICA-0, ICA-1, ICA-b or ICA-w.
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